Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03071094
Recruitment Status : Active, not recruiting
First Posted : March 6, 2017
Last Update Posted : March 12, 2020
Sponsor:
Information provided by (Responsible Party):
Transgene

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2020